Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Metastatic or Unresectable Melanoma
The purpose of this study is to determine whether relatlimab in combination with nivolumab is more effective than nivolumab monotherapy in treating unresectable melanoma or melanoma that has spread.
Age
12 - No limit years
Sex
ALL
Healthy Volunteers
No
Local Institution - 0010
Tucson, Arizona, United States
Local Institution - 0020
Los Angeles, California, United States
Coastal Integrative Cancer Care
San Luis Obispo, California, United States
Local Institution - 0116
Santa Barbara, California, United States
Local Institution - 0012
Washington D.C., District of Columbia, United States
Local Institution - 0013
Jacksonville, Florida, United States
Local Institution - 0117
Orlando, Florida, United States
Local Institution - 0007
Tampa, Florida, United States
Local Institution - 0038
Atlanta, Georgia, United States
Local Institution - 0016
Chicago, Illinois, United States
Start Date
April 11, 2018
Primary Completion Date
January 25, 2021
Completion Date
December 15, 2030
Last Updated
September 9, 2025
714
ACTUAL participants
Relatlimab
BIOLOGICAL
Nivolumab
BIOLOGICAL
Lead Sponsor
Bristol-Myers Squibb
NCT05039801
NCT06066138
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions